Metabolic and clinical effects of progestogens.
Synthetic progestogens differ not only in their hormonal potency, but also in their spectrum of hormonal activities. Beside their progestogenic and anti-oestrogenic effects, they may exert oestrogenic, androgenic, antiandrogenic, glucocorticoid and/or anti-mineralocorticoid activities. Consequently, progestogens may influence various metabolic parameters and modulate oestrogen-induced alterations in lipid metabolism, haemostasis, and various other factors. Progestogens with androgenic properties may counteract ethinyloestradiol (EE)-induced changes in lipoprotein metabolism, but do not cause atherosclerosis in the presence of EE. Oral contraceptives (OCs) containing androgenic progestogens which attenuate the EE-dependent changes in haemostasis, may be associated with a lower risk of venous thromboembolic disease than OCs whose progestogens have a less androgenic profile. Progestogens with androgenic activity may also antagonize oestrogen-induced alterations in various other hepatic proteins and modulate the effect of EE on growth factors. Progestogens with antiandrogenic activity may enhance the beneficial effect of EE in women with hyperandrogenic manifestations. Progestogens with glucocorticoid effects may increase procoagulatory activity in the vessel wall, while progestogens with anti-mineralocorticoid activity may reduce the aldosterone-induced water-retention in some women. For most women the differences in the hormonal pattern of progestogens used in OCs are without clinical relevance, but may be useful for women predisposed for the development of certain disorders.
Wiegratz
Inka
I
Department of Obstetrics and Gynaecology, J. W. Goethe University of Frankfurt, Frankfurt, Germany.
Kuhl
Herbert
H
D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy; D008660:Metabolism / Q000187:drug effects*; D011372:Progestins / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D012084:Renin-Angiotensin System / Q000187:drug effects; D013923:Thromboembolism / Q000139:chemically induced
D003280:Contraceptives, Oral, Synthetic; D011372:Progestins; D004997:Ethinyl Estradiol